angelmicin b has been researched along with cholecalciferol in 1 studies
| Studies (angelmicin b) | Trials (angelmicin b) | Recent Studies (post-2010) (angelmicin b) | Studies (cholecalciferol) | Trials (cholecalciferol) | Recent Studies (post-2010) (cholecalciferol) |
|---|---|---|---|---|---|
| 7 | 0 | 1 | 8,234 | 1,425 | 3,471 |
| Protein | Taxonomy | angelmicin b (IC50) | cholecalciferol (IC50) |
|---|---|---|---|
| Vitamin D3 receptor | Homo sapiens (human) | 0.087 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Honma, Y; Okabe-Kado, J; Oki, T; Tomoyasu, S; Tsuruoka, N; Uehara, Y; Yokoyama, A | 1 |
1 other study(ies) available for angelmicin b and cholecalciferol
| Article | Year |
|---|---|
Angelmicin B, a new inhibitor of oncogenic signal transduction, inhibits growth and induces myelomonocytic differentiation of human myeloid leukemia HL-60 cells.
Topics: Animals; Anthraquinones; Antibiotics, Antineoplastic; Cell Differentiation; Cell Division; Cholecalciferol; HL-60 Cells; Humans; Leukemia, Myeloid; Mice; Monocytes; Nitroblue Tetrazolium; Oncogenes; Protein-Tyrosine Kinases; Signal Transduction; Tretinoin; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1996 |